A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants
Stopped The study was terminated due to an unexpected preliminary result obtained from the study with CR8020.
Conditions
Interventions
- DRUG: CR8020
- DRUG: Placebo
Sponsor
Janssen Pharmaceutical K.K.